MiRNA-21 partially promotes hepatic lipid accumulation and cancer progression by interacting with the Hbp1-p53-Srebp1c pathway, miRNA-21 also regulates triglyceride and cholesterol metabolism by targeting HMGCR in NAFLD [24, 25]. Here, TP53 is linked to metabolic dysfunction-associated steatotic liver disease.